Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 17/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23671067 | 1.00 | APLNR (0.51) | APLNRL3MBTL1TAS2R14ALDH1A1TP53 | |
| SCHEMBL23670563 | 1.00 | APLNR (0.51) | APLNRL3MBTL1TAS2R14ALDH1A1TP53 | |
| SCHEMBL23670533 | 0.91 | APLNR (0.53) | APLNRL3MBTL1TAS2R14 | |
| SCHEMBL19285335 | 0.91 | APLNR (0.53) | APLNRL3MBTL1TAS2R14 | |
| SCHEMBL19284916 | 0.91 | APLNR (0.53) | APLNRL3MBTL1TAS2R14 | |
| SCHEMBL23670359 | 0.87 | APLNR (0.54) | APLNRL3MBTL1TAS2R14ALDH1A1TP53 | |
| SCHEMBL17550245 | 0.87 | APLNR (0.54) | APLNRTAS2R14 | |
| SCHEMBL19284825 | 0.87 | APLNR (0.54) | APLNRTAS2R14 | |
| SCHEMBL23669216 | 0.87 | APLNR (0.54) | APLNRL3MBTL1TAS2R14ALDH1A1TP53 | |
| SCHEMBL23669219 | 0.87 | APLNR (0.54) | APLNRL3MBTL1TAS2R14ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | APLNR 3701/4885L3MBTL1 691/4885TAS2R14 4809/4885 |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | APLNR 3701/4885L3MBTL1 691/4885TAS2R14 4809/4885 |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | APLNR 3701/4885L3MBTL1 691/4885TAS2R14 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.